Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.
Reem D MahmoodKathryn GrahamJack Patrick GleesonRichard A HubnerJuan W ValleMairéad G McNamaraPublished in: Immunotherapy (2023)
There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies.
Keyphrases
- phase ii
- clinical trial
- phase iii
- open label
- systematic review
- early stage
- papillary thyroid
- squamous cell
- double blind
- small molecule
- healthcare
- placebo controlled
- risk assessment
- meta analyses
- lymph node metastasis
- young adults
- electronic health record
- squamous cell carcinoma
- study protocol
- radiation therapy
- current status
- machine learning
- sentinel lymph node
- deep learning